Methods:
We conducted a phase 3, non-inferiority trial in healthy 2-29-year-olds in Mali and The Gambia. Participants were randomly assigned, 2:1, to receive a single intramuscular dose of NmCV-5 or MenACWY-D (Menactra). Immunogenicity was assessed at day 28. The non-inferiority of NmCV-5 compared to MenACWY-D was assessed based on differences in seroresponse rates (lower bound of 96% CI above −10%) or geometric mean titre (GMT) ratios (lower bound of 98.98% CI above 0.5). Serogroup X responses were compared to the lowest response to MenACWY-D serogroups.